Tuberculosis vaccines: a strategic blueprint for the next decade.
about
Translational Research for Tuberculosis Elimination: Priorities, Challenges, and ActionsTuberculosis vaccines and prevention of infectionThe Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85 Complex of M. tuberculosisTuberculosis: From an incurable scourge to a curable disease - journey over a millenniumAdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human PrimatesIncreased B and T Cell Responses in M. bovis Bacille Calmette-Guérin Vaccinated Pigs Co-Immunized with Plasmid DNA Encoding a Prototype Tuberculosis AntigenA review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy dataRegulation of TB vaccine-induced airway luminal T cells by respiratory exposure to endotoxinDriving the Way to Tuberculosis Elimination: The Essential Role of Fundamental ResearchSafety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trialAge at Mycobacterium bovis BCG Priming Has Limited Impact on Anti-Tuberculosis Immunity Boosted by Respiratory Mucosal AdHu5Ag85A Immunization in a Murine ModelR&D in Vaccines Targeting Neglected Diseases: An Exploratory Case Study Considering Funding for Preventive Tuberculosis Vaccine Development from 2007 to 2014.The next 10 years for tuberculosis vaccines: do we have the right plans in place?A New Rabbit-Skin Model to Evaluate Protective Efficacy of Tuberculosis Vaccines.Exosomes carrying mycobacterial antigens can protect mice against Mycobacterium tuberculosis infection.Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85AImmune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.Comparison of the predicted population coverage of tuberculosis vaccine candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a bioinformatics approach.Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countriesThe tuberculin skin test in school going adolescents in South India: associations of socio-demographic and clinical characteristics with TST positivity and non-response.TB incidence in an adolescent cohort in South AfricaMultiple consecutive infections might explain the lack of protection by BCG.Genomic analysis of a Mycobacterium bovis bacillus [corrected] Calmette-Guérin strain isolated from an adult patient with pulmonary tuberculosis..Helicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis.Willingness to participate in trials and to be vaccinated with new tuberculosis vaccines in HIV-infected adultsNonclinical Development of BCG Replacement Vaccine Candidates.Incidence of tuberculosis among school-going adolescents in South India.Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.The role of biomedical research in global tuberculosis control: gaps and challenges: A perspective from the US National Institute of Allergy and Infectious Diseases, National Institutes of Health.A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis.Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.Immunogenic Properties of Lactobacillus plantarum Producing Surface-Displayed Mycobacterium tuberculosis Antigens.Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time.Challenges in the research and development of new human vaccines.Early clearance of Mycobacterium tuberculosis: a new frontier in prevention.Aerosol immunisation for TB: matching route of vaccination to route of infectionMycobacterium tuberculosis virulence: insights and impact on vaccine development.High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines.
P2860
Q26765051-735BC8C4-9AEF-43CE-8C10-7D200DDB9457Q26782022-65E1BD03-C280-4624-AB7F-A3C36641FAECQ26852552-9080EC9E-14B8-4C17-8C4E-BD7637E8209DQ26865560-CDD6C884-E685-48D9-8B2D-7AB6BD919C4CQ27300923-A319042E-FA45-460C-AECC-DACE51B4BB84Q27302995-3ADD58EC-ABB7-44E7-ABB8-2FD06C373CC3Q28383049-CC50587F-2CAC-44F3-8706-2DF1AB06A532Q28386706-A483A634-1499-4A06-987F-B4B016C9557DQ28388018-63557365-B16A-40CC-903F-FB0AA891CE90Q29620144-2D1082A5-BA81-4396-9099-20C0943DA302Q30375962-202BDC3D-6DB4-41CB-9D4A-4A4386B8F583Q30379192-8EBFCF9B-3155-4C7C-B59F-CB4937476205Q33659150-E2EACA3A-0D23-41AE-AED2-F780BF1AA329Q33697290-2C7DE723-ED39-4BFC-9AB9-2DFCC772FC5AQ33827831-18403058-34E1-46E1-AA11-47930B82F66BQ33899366-40CE5783-5134-4BB7-A0E2-EFD38CBB77B9Q34146613-29A6991A-5386-4D72-B1F5-8F76413185D1Q34345342-DA5A1D60-FD5A-4042-A3F0-0FC811EA55D8Q34441930-B61926E9-CB3C-4F76-AB64-B4B1DF83AE1EQ34570177-EC06B188-9A91-4F03-8862-D12DE3CF5A62Q34637907-0DCA72A8-61D2-4862-8F68-8152864601E9Q35150684-E0767172-6D69-4B1A-9FBA-EFB58B7AAF24Q35390426-6431B40C-A752-4295-BCC5-F7341BD02FEFQ35573126-6A47F634-FF0D-4B0C-8332-2682645B9DBCQ35719108-2682D970-BA32-465A-A7F8-B01C8D7E9B99Q35890636-2D10C0C8-2298-4B96-B67F-63B0CACE9078Q36086728-DB543B7C-FA8D-45A0-849A-1F10F92341E6Q36287555-C4D97E55-3AAE-4891-8DB2-71B9183F0BC5Q36779704-DB1B0DC7-0F3A-4000-AC62-DD185C461896Q37135418-1080F593-9FCE-42BE-A7A1-F3AC96BF0000Q37335461-AB85B706-DA89-44CE-8251-E375E3ECE34CQ37546883-8FB6A42E-0C16-4AD2-95CE-B331BCCACBB3Q37621760-41EF1DCD-8248-4E41-A229-43FC32CBFD26Q37671936-69678110-E32B-454A-B3D5-1DB8CEB16AD6Q38041566-FB5A9680-4D12-4DDD-92D1-B89F4BD292A5Q38096300-4A22D33E-A3C1-49D1-9064-B98D7B47E360Q38206209-C43CAC6F-F4F2-4453-80E2-9CF0708F105FQ38338183-150D5B43-A853-4C70-9FC9-776D5549E29DQ38539493-6725E4B8-6462-47C8-909B-6C75BA1D553EQ39042197-1BDEDAAB-EA24-487B-A646-3B564EC7C161
P2860
Tuberculosis vaccines: a strategic blueprint for the next decade.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tuberculosis vaccines: a strategic blueprint for the next decade.
@en
Tuberculosis vaccines: a strategic blueprint for the next decade.
@nl
type
label
Tuberculosis vaccines: a strategic blueprint for the next decade.
@en
Tuberculosis vaccines: a strategic blueprint for the next decade.
@nl
prefLabel
Tuberculosis vaccines: a strategic blueprint for the next decade.
@en
Tuberculosis vaccines: a strategic blueprint for the next decade.
@nl
P1433
P1476
Tuberculosis vaccines: a strategic blueprint for the next decade.
@en
P2093
Jelle Thole
Michael J Brennan
P356
10.1016/S1472-9792(12)70005-7
P478
92 Suppl 1
P577
2012-03-01T00:00:00Z